全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:V. E. Goldberg , T. Yu. Polyakova , N. O. Popova ...
来源:[J].Bulletin of Experimental Biology and Medicine(IF 0.341), 2017, Vol.163 (4), pp.469-474Springer
摘要:The toxic effects of combined cisplatin/docetaxel therapy cycles on erythroid and granulocytic hematopoietic lineages as well as their intercycle recovery were examined in patients with stage III-IV non-small-cell lung carcinoma. Responsiveness of the blood system to this therapy...
作者:Guowei Zhang , Hao Zheng , Guojun Zhang ...
来源:[J].Cancer Cell International(IF 2.093), 2017, Vol.17 (1)Springer
摘要:Lung cancer is the major cause of cancer-related death worldwide, and 80% patients of lung cancer are non-small-cell lung cancer (NSCLC) cases. MicroRNAs are important gene regulators with critical roles in diverse biological processes, including tumorigenesis. Studies indicate t...
作者:Sato S , Itamochi H
来源:[J].OncoTargets and Therapy(IF 2.073), 2016, Vol.2016 (Issue 1), pp.1181-1188DOAJ
摘要:... In contrast, FRΑ is overexpressed in epithelial ovarian cancer (EOC) and non-small-cell lung carcinoma. Therefore, FRΑ is considered a promising therapeutic target for EOC and non-small-cell lung carcinoma. Farletuzumab (MORAb-003) is a humanized monoclonal antibody of ...
作者:Zijun Yin , Meng Xu , Ping Li
来源:[J].Gene(IF 2.196), 2017, Vol.620, pp.46-53Elsevier
摘要:... However, expression pattern and role of miRNA-221 in the non-small-cell lung carcinoma (NSCLC) remains poorly understood. In the current study, we explored the roles and the underlying mechanism of miR-221 in NSCLC by gain and loss of function analysis. We found that the expr...
作者:Song Y , Li A , Zhang L ...
来源:[J].OncoTargets and Therapy(IF 2.073), 2016, Vol.2016 (Issue 1), pp.4105-4112DOAJ
摘要:... The aim of this study is to determine the relationship of GPR56 expression with clinicopathological parameters and prognosis in non-small-cell lung carcinoma (NSCLC).Methods: The levels of GPR56 were evaluated by immunohistochemistry in 157 NSCLC tissue samples. The assoc...
作者:Bai H , Xu J , Yang H ...
来源:[J].OncoTargets and Therapy(IF 2.073), 2016, Vol.2016 (Issue 1), pp.4207-4213DOAJ
摘要:Hao Bai,1,* Jianlin Xu,1,* Haitang Yang,2,* Bo Jin,1 Yuqing Lou,1 Dan Wu,3 Baohui Han1 1Department of Pulmonary, 2Department of Pathology, 3Central Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China *These authors contributed equally to this work Introduction: Clinical evidence for patients with synchronous brain oligometastatic non-small-cell...
作者:Min Ki Lee , Jae Ho Kim , Chang Hun Lee ...
来源:[J].Pathology(IF 2.657), 2006, Vol.38 (6), pp.555-560Elsevier
摘要:... This study was performed to investigate BGP expression in non-small-cell lung carcinoma (NSCLC).(#br)Methods(#br)A total of 119 cases of NSCLC, including 63 squamous cell carcinomas (SqCCs) and 56 adenocarcinomas (ACs), were imunohistochemically evaluated for BGP expressi...
作者:Constantinos Giaginis , Paraskevi Alexandrou , Nikolaos Tsoukalas ...
来源:[J].Tumor Biology(IF 2.518), 2015, Vol.36 (1), pp.315-327Springer
摘要:... The present study aimed to evaluate the clinical significance of HuR and COX-2 protein expression in non-small-cell lung carcinoma (NSCLC). HuR and COX-2 expression was assessed immunohistochemically on tissue microarrays of 81 surgically resected NSCLC and was analyzed in r...
作者:Song X , Shi K , Zhou SJ ...
来源:[J].Drug Design, Development and Therapy(IF 3.486), 2016, Vol.2016 (Issue 1), pp.1345-1354DOAJ
摘要:Xiaoyun Song,* Kang Shi,* Shi-Jie Zhou, Da-Ping Yu, Zhidong Liu, Yi Han Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing, People’s Republic of China *These authors contributed equally to this work Abstract: Lung cancer is the leadi...
作者:Wu X , Wu G , Yao X ...
来源:[J].Drug Design, Development and Therapy(IF 3.486), 2016, Vol.2016 (Issue 1), pp.699-709DOAJ
摘要:Xiaoyu Wu,1,* Guannan Wu,1,* Xuequan Yao,1 Gang Hou,2 Feng Jiang3 1Department of Surgical Oncology, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, 2Department of Respiratory Medicine, The First Hospital of China Medical University, Shenyang, 3Department of Thoracic Surgery, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People’s Republic of China *These authors contributed equally to this work Abstract: Emerging evidence indicates that FHIT is a candidate tumor suppressor in many types of tumors including non-small-cell...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×